


Activities of the working party and subcommittees

Chair: Ibrahim Yakoub-Agha

Secretary: Patrick Hayden

E-mail address: cmwpebmt@lumc.nl

### Subcommittee Chronic Myeloid Leukemia

Chair: Yves Chalandon


#### Selected Upcoming Analyses CML 2020


 Prognostic value of additional cytogenetic abnormalities in CML patients at transplantation.  
*Caers J et. al*

 Outcome of CML post haplo-identical cell transplantation as compared to MRD and MUD.  
*Onida F et. al*

 Comparison of haplo-identical (HID) transplant to matched sibling donor (MRD) and MUD in patients with CML blast crisis (de novo or secondary).  
*Sheth V*

 Post-Transplant Scoring System for CML Based on Retrospective Analysis of Patients Surviving more than 100 Days after Allogeneic HSCT.  
*Mappoura M et. al*

### Subcommittee Myelodysplastic Syndromes

Chair: Marie Robin, Vice-chair: Christof Scheid, CMML: Francesco Onida


#### Call for patient identification

Myelodysplastic Syndromes (MDS) and Paroxysmal Nocturnal Hemoglobinuria (PNH)

On behalf of the Severe Aplastic Anemia Working Party (SAAWP) and the Chronic Malignancies Working Party (CMWP), we are looking for centers that have treated patients with one of the two below clinical associations of PNH with MDS:

1. MDS with PNH clones – with small PNH clones and no evidence of haemolysis (the subclinical PNH)
2. MDS-PNH syndromes – with clinical and laboratory evidence of haemolysis (the clinical PNH)

If you have treated such a patient, please send the Unique Identification Code (UIC) to cmwpebmt@lumc.nl.

#### Active data request

Outcomes of patients who received an allogeneic hematopoietic stem cell transplantation (HSCT) for MDS or (s)AML after a prior diagnosis of a plasma cell disorder (PCD)

Inclusion criteria:

- Diagnosis of PCD prior to the first allogeneic HSCT.
- MDS or (s)AML as main indication diagnosis for first allogeneic HSCT.
- Adults ( $\geq 18$  years) at time of first allogeneic HSCT.
- First allogeneic HSCT between 2006 and 2018.


If you have potential eligible patients and did not receive the data request, please contact us at cmwpebmt@lumc.nl

### Poster Session

#### ePoster Area Myelodysplastic syndromes

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Therapy-Related Myeloid Neoplasm: A Study from the Chronic Malignancies Working Party of the EBMT

### Subcommittee Ph-neg MPN

Chair: Donal McLornan, Vice-chair: Juan Carlos Hernández-Boluda, Tomasz Czerw


#### Selected Upcoming Analyses MPN 2020

Senior author: Ibrahim Yakoub-Agha

The role of spleen size and splenectomy in determining outcome in allogeneic stem cell transplantation for Myelofibrosis.

*Polverelli N et. al*

The role of Thiotepa-busulfan-fludarabine conditioning in allogeneic stem cell transplantation for Myelofibrosis.

*Battipaglia G et. Al*

Post-Transplant Cyclophosphamide as GvHD Prophylaxis for Allogeneic Hematopoietic Stem Cell Transplantation for myelofibrosis as compared to standard GvHD prophylaxis: A CMWP Study

*Chalandon Y et al.*

### Poster Session

#### ePoster Area Chronic leukaemia and other myeloproliferative disorders

Determinants of Survival in Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Cell Transplantation: A Study by the Chronic Malignancies Working Party of EBMT

### Recently published articles

#### Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation

Raj K, Eikema DJ, McLornan DP, Olavarria E, Blok HJ, Bregante S, Ciceri F, Passweg J, Ljungman P, Schaap N, Carlson K, Zuckerman T, de Weede LC, Volin L, Koc Y, Diez-Martin JL, Brossart P, Wolf D, Blaise D, Di Bartolomeo P, Vitek A, Robin M, Yakoub-Agha I, Chalandon Y, Kröger N. *Biology of Blood and Marrow Transplantation* Mar;25(3):522-528. doi:10.1016/j.bbmt.2018.10.017.

#### State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019

McLornan DP, Yakoub-Agha I, Robin M, Chalandon Y, Harrison CN, Kröger N. *Haematologica* Apr;104(4):659-668. doi:10.3324/haematol.2018.206151.

#### Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party

Radujkovic A, Dietrich S, Blok HJ, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sora F, Passweg J, Byrne JL, Jindra P, Veelken JH, Socie G, Maertens J, Schaap N, Stadler M, Itala-Remes M, Tholouli E, Arat M, Rocha V, Ljungman P, Yakoub-Agha Z, Kröger N, Chalandon Y. *Biology of Blood and Marrow Transplantation* Oct;25(10):2008-2016. doi:10.1016/j.bbmt.2019.06.028.

#### A prospective study on the Impact of Transfusion Burden and Related Iron Toxicity on Outcome in Myelodysplastic Syndrome undergoing Haematopoietic Cell Transplantation

Cremers EMP, de Witte T, de Weede L, Eikema DJ, Koster L, van Biezen A, Finke J, Socié G, Beelen D, Maertens J, Nagler A, Kobbe G, Ziegkos D, Itala-Remes M, Gedde-Dahl T, Sierra J, Niederwieser D, Ljungman P, Beguin Y, Nur Ozkurt Z, Anagnostopoulos A, Jindra P, Robin M, Kröger N. *Leukemia and Lymphoma* Oct;60(10):2404-2414. doi:10.1080/10428194.2019.1594215.

#### Myeloablative and Reduce-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

McLornan D, Szyszlo R, Koster L, Chalandon Y, Robin M, Wolschke C, Beelen D, Socié G, Bornhäuser M, Angelucci E, Niederwieser D, Gerbitz A, Finke J, Vitek A, Itala-Remes M, Radujkovic A, Kanz L, Potter V, Chevallier P, Steljes M, Petersen E, Robinson S, Poiré X, Klyuchnikov E, Hernández-Boluda JC, Czerw T, Hayden P, Kröger N, Yakoub-Agha I. *Biology of Blood and Marrow Transplantation* Nov;25(11):2167-2171. doi:10.1016/j.bbmt.2019.06.034.

#### Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allograft: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation

Carré M, Porcher R, Finke J, Ehninger G, Koster L, Beelen D, Ganser A, Volin L, Lozano S, Friis L, Michallet M, Tischer J, Olavarria E, Cascon MJP, Iacobelli S, Koc Y, Jindra P, Arat M, de Witte T, Yakoub-Agha I, Kröger N, Robin M. *Biology of Blood and Marrow Transplantation* in press. doi:10.1016/j.bbmt.2019.10.015.

#### Outcome of allogeneic hematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT

McLornan DP, Malpassuti V, Lippinkhof-Kozijn A, Potter V, Beelen D, Bunjes D, Sengeloev H, Radujkovic A, Passweg J, Chalandon Y, Kröger N, Wulf GG, Johansson J, Ciceri F, Bornhäuser M, Holler E, Guffroy B, Martin S, Neubauer A, Gramatski M, Robin M, Iacobelli S, Hayden P, Hernández-Boluda JC, Czerw T, Yakoub-Agha I. *British Journal of Haematology*, in press. doi:10.1111/bjh.16537

#### Determinants of Survival in Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Hernández-Boluda, Pereira A, Kröger N, Beelen D, Robin M, Bornhäuser M, Angelucci E, Vitek A, Blau IG, Niityvuopio R, Finke J, Cornelissen JJ, Passweg J, Dreger P, Petersen E, Kanz L, Sanz J, Zuckerman T, Zinger N, Iacobelli S, Hayden P, Czerw T, McLornan D, Yakoub-Agha I. *Leukemia*, in press. doi:10.1038/s41375-020-0815-z